Clinical Study for Levocarnitine on Improving Ultrafiltration Function of Peritoneal Dialysis patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022913

Enrollment

Unknown

Registered

2019-05-01

Start date

2019-08-01

Completion date

Unknown

Last updated

2019-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic renal

Interventions

Experimental group:Standard glucose-containing peritoneal dialysate exchange plus L-carnitine

Control group:Standard glucose-containing peritoneal dialysate exchange

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) For non-diabetic CAPD patients over 3 months, 2L*4 bags of peritoneal dialysis per day; (2) Peritoneal balance test: creatinine ratio of peritoneal dialysis fluid to plasma: 0.50-0.81, and glucose ratio of peritoneal dialysis fluid to plasma: 0.26-0.49.

Exclusion criteria

Exclusion criteria: (1) Received L-carnitine in recent January; (2) Peritonitis and type 2 diabetes mellitus occurred in recent March; (3) Hb was less than 85g/L, with severe diseases or acute infections; (4) congestive heart failure; (5) Malignant tumors.

Design outcomes

Primary

Measure	Time frame
Ultrafiltration in peritoneal dialysis;	—

Secondary

Measure	Time frame
Levocarnitine concentration;	—

Countries

China

Contacts

Public ContactXIANG AO

Department of Nephrology, Xiangya Hospital, Central South University

38910847@qq.com+86 13975806025

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026